Barbara Tilley to Disease Progression
This is a "connection" page, showing publications Barbara Tilley has written about Disease Progression.
Connection Strength
0.554
-
Non-linearity of Parkinson's disease progression: implications for sample size calculations in clinical trials. Clin Trials. 2005; 2(6):509-18.
Score: 0.182
-
Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson's Disease: An?Analysis?of?NET-PD LS1. J Parkinsons Dis. 2017; 7(1):117-127.
Score: 0.104
-
Caffeine and Progression of Parkinson Disease: A Deleterious Interaction With Creatine. Clin Neuropharmacol. 2015 Sep-Oct; 38(5):163-9.
Score: 0.095
-
Autonomic and electrocardiographic findings in Parkinson's disease. Auton Neurosci. 2017 07; 205:93-98.
Score: 0.027
-
Caffeine, creatine, GRIN2A and Parkinson's disease progression. J Neurol Sci. 2017 Apr 15; 375:355-359.
Score: 0.026
-
Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. JAMA. 2015 Feb 10; 313(6):584-93.
Score: 0.023
-
Measuring disease progression in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience. JAMA Neurol. 2014 Jun; 71(6):710-6.
Score: 0.022
-
The MDS-UPDRS Part II (motor experiences of daily living) resulted useful for assessment of disability in Parkinson's disease. Parkinsonism Relat Disord. 2013 Oct; 19(10):889-93.
Score: 0.020
-
Subject-investigator reproducibility of the Unified Parkinson's Disease Rating Scale. Parkinsonism Relat Disord. 2012 Mar; 18(3):230-3.
Score: 0.018
-
Caffeine and progression of Parkinson disease. Clin Neuropharmacol. 2008 Jul-Aug; 31(4):189-96.
Score: 0.014
-
A responsive outcome for Parkinson's disease neuroprotection futility studies. Ann Neurol. 2005 Feb; 57(2):197-203.
Score: 0.011
-
Antiphospholipid-protein antibodies and acute ischemic stroke in the NINDS rt-PA Stroke Trial. Neurology. 2003 Oct 28; 61(8):1158-9.
Score: 0.010